Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
INMB 
INmune Bio Inc (INMB)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/12/2025: INMB (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.25
1 Year Target Price $5.25
| 2 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -6.56% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 53.44M USD | Price to earnings Ratio - | 1Y Target Price 5.25 |
Price to earnings Ratio - | 1Y Target Price 5.25 | ||
Volume (30-day avg) 5 | Beta 0.92 | 52 Weeks Range 1.38 - 10.50 | Updated Date 12/13/2025 |
52 Weeks Range 1.38 - 10.50 | Updated Date 12/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -69724% |
Management Effectiveness
Return on Assets (TTM) -50.59% | Return on Equity (TTM) -155.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 26782368 | Price to Sales(TTM) 1068.73 |
Enterprise Value 26782368 | Price to Sales(TTM) 1068.73 | ||
Enterprise Value to Revenue 535.65 | Enterprise Value to EBITDA -5.31 | Shares Outstanding 26585258 | Shares Floating 20608626 |
Shares Outstanding 26585258 | Shares Floating 20608626 | ||
Percent Insiders 24.61 | Percent Institutions 17.61 |
About INmune Bio Inc
Exchange NASDAQ | Headquaters Boca Raton, FL, United States | ||
IPO Launch date 2019-02-04 | President, CEO, Treasurer, Secretary & Director Mr. David J. Moss M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://www.inmunebio.com |
Full time employees 13 | Website https://www.inmunebio.com | ||
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.